Form 4: Aethlon Medical Director, Chetan Shah, Acquires Shares Through Restricted Stock Units

Director Chetan Shah acquired 142,857 shares of Aethlon Medical Inc. through restricted stock units (RSUs) at a price of $0.358 per share.

Summary

• On April 23, 2025, Chetan Shah, a director of Aethlon Medical Inc., acquired 142,857 shares of common stock through the grant of Restricted Stock Units (RSUs).
• The price per share was $0.358.
• Following the transaction, Shah directly owns 174,233 shares of Aethlon Medical Inc.
• The RSUs vest in four equal quarterly installments starting June 30, 2025, and ending March 31, 2026, contingent upon continued service with the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider ownership is generally viewed favorably, but the impact is limited as it's a planned RSU grant.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The RSUs vest over time, contingent on continued service, aligning the director's interests with the long-term success of the company.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's valuation and future performance. RSU grants are a common form of executive compensation in the biotech industry.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Aethlon Medical, AEMD, Form 4, Insider Trading, Chetan Shah, Director, RSU, Restricted Stock Units, Beneficial Ownership